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Abstract
Background: Foot orthoses are frequently used but little is known about which types are used in contemporary
practice. This study aimed to explore the types of foot orthoses currently used by podiatrists and the prescription
variations in a range of conditions.
Methods: A web-based, cross-sectional survey was distributed through professional bodies in the United Kingdom
(UK), Australia, and New Zealand. Questions focussed on foot orthosis prescription habits in relation to 26
conditions affecting the back and lower limb.
Results: Two hundred and sixty-four podiatrists practising in 19 different countries completed the survey; the majority
practised in the UK (47%, n = 124), Australia (30%, n = 79) and New Zealand (12%, n = 32). Respondents qualified
between 1968 and 2016, and 147 (56%) were female. Respondents worked in different healthcare sectors and this
varied between countries: 42 (34%) respondents in the UK worked solely in the public sector, compared to 3 (4%) in
Australia and 2 (6%) in New Zealand. Forty-four (35%) respondents in the UK worked solely in private practice,
compared to 64 (81%) in Australia and 14 (44%) in New Zealand.
UK respondents prescribed more prefabricated orthoses per week (mean 5.5 pairs) than simple insole-type devices (±2.
7) and customised devices (±2.9). Similarly, respondents in New Zealand prescribed more prefabricated orthoses per
week (±7.7) than simple (±1.4) and customised (±2.8) devices. In contrast, those in Australia prescribed more
customised orthoses per week (±4.4) than simple (±0.8) and prefabricated (±1.9) orthoses. Differences in the types of
orthoses prescribed were observed between country of practice, working sector, and the condition targeted. Generally,
prefabricated orthoses were commonly prescribed for the 26 highlighted conditions in the UK and New Zealand.
Australian podiatrists prescribed far fewer devices overall, but when they did prescribe, they were more likely to
prescribe custom devices. Respondents in all three countries were more likely to prescribe customised orthoses for
people with diabetes complicated by peripheral neuropathy than for diabetes without this complication.
Conclusions: Foot orthosis prescription habits vary between countries. Prefabricated orthoses were frequently
prescribed in the UK and New Zealand, and customised orthoses in Australia. Prescriptions for people with diabetes
differed depending on the presence of neuropathy, despite a lack of robust evidence supporting these decisions. This
study provides new insight into contemporary practice.
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Background
Foot orthoses (FOs) are frequently prescribed by podia-
trists for a variety of foot and lower limb conditions.
They range considerably in terms of their design but can
be broadly divided into two categories: (i) accommoda-
tive or simple FOs, which provide cushioning and off-
loading of structures, or (ii) functional FOs, which aim
to systematically alter abnormal foot mechanics and
function to alleviate symptoms. Functional FOs can be
further categorised as either customised or prefabricated
FOs [1]. A ‘customised’ FO is tailored to the individual
based on a 3-dimensional (3D) model of the plantar as-
pect of the foot, whereas prefabricated FOs are
mass-produced to a generic foot shape [2, 3].
Although their exact mechanism of action remains un-
clear, FOs are thought to alter the mechanics of the feet
and lower limb in a systematic way. Both accommoda-
tive and functional FOs are reported to help a range of
lower limb pathologies [4–9] by alleviating symptoms [8,
9] improving function [10], preventing deformity [11],
and preventing injury [12]. As such, they are now rec-
ommended in national guidelines for a number of condi-
tions, including rheumatoid arthritis [13], osteoarthritis
(OA) [14], and diabetes [15].
The cost of providing FOs remains an ongoing issue
for healthcare providers, patients and practitioners. A re-
cent exploratory clinical trial [16] that also evaluated
cost effectiveness found that a pair of customised FOs
were £52.60 more expensive to produce than a simple
FO when costed from a National Health Service (NHS)
perspective, and £80.00 more expensive from an NHS
and societal perspective. The authors of this trial attrib-
uted these additional costs to manufacturing time and
cost of materials used in the manufacturing process.
Similarly, the labour, materials and laboratory costs in-
curred in a previous trial [3] indicated that customised
FOs were 3.5 times more costly than prefabricated de-
vices at the point of issue. Clearly, cost differences exist
between these orthotic devices, however there is evi-
dence that indicates similarities in function between cer-
tain FO types. For example, studies have shown that
some contoured prefabricated FOs exhibit similar phys-
ical characteristics to customised FOs [3, 17], and can
reduce patient symptoms for certain conditions to the
same extent as customised devices [5]. The use of pre-
fabricated FOs may therefore lead to substantial poten-
tial healthcare cost savings without compromising
treatment effectiveness [18].
Although the use of FOs in clinical practice appears to
be widespread, evidence and guidelines relating to the
prescription of FOs are limited, and consequently there
is no broad consensus on the best type of insole to use
for specific conditions. FO prescriptions may therefore
vary extensively between clinicians [19, 20], but very
little is known about how prescription habits differ
across countries and according to pathology. In 2001,
Landorf et al. [7] explored the types of FOs used within
podiatric practice in Australia and New Zealand and
found that the majority (72%) of respondents prescribed
customised FOs most often, although respondents in
New Zealand were three times more likely than those in
Australia to prescribe prefabricated FOs. More recently,
Menz et al. [21] analysed prescription characteristics of
custom-made foot orthoses from a single orthotic la-
boratory in Australia, and identified that prescriptions
were influenced by the extent of the patient’s rearfoot
pronation, the age and sex of the patient, and the clini-
cian’s geographic location. Nester et al. [22] surveyed po-
diatrists, physiotherapists and orthotists in the United
Kingdom (UK), and found that prefabricated FOs were
used by 93% of respondents, although 75% also provided
customised FOs as part of their practice.
Despite comparable education and scope of podiatric
practice, no previous studies have directly compared FO
prescription habits among podiatrists in the UK,
Australia and New Zealand. Furthermore, no research
has to date provided insight into the types of FOs pre-
scribed for specific presentations or conditions com-
monly affecting the lower limb. Information on the FOs
currently in use is vital to establish a benchmark of con-
temporary practice, ensuring that future research evalu-
ating the clinical and cost effectiveness of FOs is
relevant to practice.
The aims of the current study were to describe and
compare the types of FOs currently prescribed by podia-
trists across the UK, Australia and New Zealand, and to
determine whether the type of FO prescribed varies be-
tween a range of common presentations and conditions
affecting the back and lower limb.
Methods
The study utilised a cross-sectional, online,
self-administered survey to elicit the FO prescription habits
of registered podiatrists in the UK, Australia and New Zea-
land. Ethical approval was received from the School of
Medicine Research Ethics Committee, University of Leeds
(Ref: MREC15–052). Subsequent approval was also gained
from La Trobe University (Ref: MREC15–052) and Auck-
land University (Ref: 16/133) of Technology. Consent was
implied by completion of the survey and it was accessible
from June 2016 to November 2016.
Survey design
Survey questions were developed by experienced clini-
cians and experts in FO research and piloted with
user groups of local podiatrists. The final survey
(Additional file 1) consisted of 29 questions that were
arranged into three sections. The first section of the
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survey was designed to elicit demographic and de-
scriptive data from participants, including gender, year
qualified, country of practice, country in which pri-
mary podiatry qualification was undertaken, percent-
age of clinical time spent working in the public sector
and private practice, and the two patient groups most
frequently treated. Participants were also asked to re-
port the quantity of simple, prefabricated and custo-
mised FOs prescribed per week, and the extent of
free choice they had when prescribing FOs.
The second section was designed to elicit the type of FO
most frequently prescribed for patients with 26
pre-selected presentations and medical conditions affect-
ing the back and lower limb, which included the following:
back pain, hip pain, knee pain, patellofemoral pain, shin
splints/poster-medial leg pain, ankle pain, Achilles ten-
donitis, rearfoot pain, plantar heel pain/plantar fasciitis,
peroneal tendonitis, tibialis posterior tendon dysfunction,
midfoot osteoarthritis, forefoot pain/metatarsalgia, Mor-
ton’s neuroma, 1st metatarsophalangeal joint osteoarth-
ritis, diabetes with and without peripheral neuropathy,
non-inflammatory musculoskeletal disease (e.g. osteoarth-
ritis), seronegative arthritis, connective tissue disease,
gout, neurological diseases, neuromuscular conditions,
and falls prevention in older adults. The survey also cap-
tured data relating to early and established rheumatoid
arthritis, the results of which will be included in a future
publication. An electronic survey technique was used, uti-
lising the Bristol Online Survey website (http://onlinesur-
veys.ac.uk) to enable international completion.
Terminology
In the absence of universally agreed definitions of foot
orthosis (FO) types, FOs were grouped into three cat-
egories. Simple FOs were considered as flat insoles with
or without padding to accommodate painful areas or le-
sions. Prefabricated FOs were considered as devices
made to a generic foot shape, contoured for the arch,
and included modular prefabricated FOs that can be al-
tered by clinicians (e.g. by the addition of heel posting,
wedges, pads or top covers). Customised FOs were con-
sidered as devices manufactured for a specific person
based on a 3D impression or computerised image of that
person’s foot, and produced using computer aided de-
vice/manufacturing (CAD/CAM) or more traditional
manufacturing techniques (e.g. foam impression box or
plaster of Paris cast).
Participants
Participants were invited to complete the anonymous
online survey via professional bodies, national profes-
sional e-newsletters, special interest groups, discussion
forums, and professional publications, across the UK,
Australia and New Zealand. These countries were
selected due to similar education and broadly compar-
able scopes of clinical practice in place. Data from podi-
atrists practising in any other countries who participated
in the survey were excluded from the main analysis due
to potential differences in education and scope of prac-
tice, but were presented as supplementary data. The sur-
vey was also promoted at local and regional meetings
during the study period. To be eligible to complete the
survey, participants had to be registered podiatrists, able
to access the survey online, and understand written Eng-
lish. As the open invitation survey distribution method
was designed to maximise participation, there was no
denominator available to estimate the response rate.
Analysis
Survey data was analysed with IBM SPSS v 21 (Armonk,
NY: IBM Corp) using descriptive statistics. All data were
described as mean (SD) for continuous data and n (%)
for categorical data.
Results
Demographics
Two hundred and sixty-four podiatrists practising in 19
countries completed the survey. Of these, 147 (56%) were
female. Respondents qualified between 1968 and 2016
with a mean (SD) of 16.9 (11.8) years since qualifying. Re-
spondents practising in England, Scotland, Wales and
Northern Ireland were combined as the UK. The majority
of respondents practised in the UK (47%, n = 124),
Australia (30%, n = 79) and New Zealand (12%, n = 32).
Results from respondents practising outside these three
countries (11%, n = 29) are not detailed but an overview is
presented as supplementary data (see Additional file 2).
An overview of the type of health sector in which re-
spondents in each country worked is shown in Table 1.
Comparisons between the public sector and private
practice were not made among respondents in Australia
or New Zealand due to the limited number of respon-
dents working solely in the public sector.
UK respondents most frequently treated people with
non-inflammatory musculoskeletal conditions (Fig. 1).
However, UK respondents working in private practice
most frequently treated general practice/core podiatry
patients (providing routine foot care, such as nail care
and callus debridement) (Fig. 2). Respondents in
Australia and New Zealand also most frequently treated
general practice/core podiatry patients (Fig. 1).
Quantity and type of FOs prescribed
Overall, prescription rates were higher amongst re-
spondents in New Zealand and the UK, compared to
Australian respondents (Fig. 3). Respondents practis-
ing in the UK prescribed more prefabricated FOs per
week than customised or simple FOs. UK respondents
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prescribed the highest mean number of simple FOs
per week compared to any other country (Fig. 3). UK
respondents working in the public sector prescribed
more prefabricated FOs per week than other FO types
and over three times as many prefabricated FOs per
week as those working in private practice (Table 2),
whilst the provision of customised FOs was similar in
both sectors. Among UK respondents working in pri-
vate practice, more customised FOs were prescribed
than prefabricated FOs and simple FOs, although dif-
ferences were small (Table 2).
Although respondents in Australia prescribed fewer
FOs per week than those in the UK and New
Zealand, they had a higher mean number of custo-
mised FO prescriptions. They also prescribed more
customised FOs per week than prefabricated FOs or
simple FOs (Fig. 3). Respondents in New Zealand pre-
scribed more prefabricated FOs per week than custo-
mised FOs or simple FOs, and more prefabricated
FOs than those in Australia and the UK.
When asked about simple FOs, 16 (13%) respondents
in the UK stated that they did not prescribe these
devices. Similarly, 13 (17%) Australian respondents, and
seven (22%) New Zealand respondents, did not prescribe
simple FOs.
When asked about prefabricated FOs, 13 (11%) UK
respondents indicated that they did not prescribe
these devices. Similarly, four (5%) Australian respon-
dents, and one (3%) New Zealand respondent indi-
cated they did not prescribe prefabricated FOs.
When asked about customised FOs, 25 (20%) UK re-
spondents stated that they did not prescribe these de-
vices. In contrast, two (3%) respondents practising in
Australia, and none (0%) of the respondents practising
in New Zealand, stated they did not prescribe custo-
mised FOs.
Extent of choice when prescribing
Respondents in the UK had the least choice of
which FO type (simple, prefabricated or customised)
to prescribe, compared to respondents in Australia
and New Zealand, and were more likely to have to
select from a pre-determined list or stock (Fig. 4).
Respondents in New Zealand had more choice than
those in Australia when prescribing prefabricated
FOs, while Australian respondents had more choice
than those in New Zealand when prescribing custo-
mised FOs (Fig. 4). UK respondents working in the
public sector had less free choice when prescribing
all FO types than those working in private practice
(Table 2).
Table 1 Type of sector in which clinical time is spent
Country of
practice
Solely public
sector
Solely private
practice
Combination
UK 42 (34%) 44 (35%) 38 (31%)
Australia 3 (4%) 64 (81%) 12 (15%)
New Zealand 2 (6%) 14 (44%) 16 (50%)
Fig. 1 Most frequently treated patient groups
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FO prescription habits for specific presentations and
conditions
Table 3 illustrates the range of FO prescription choices
made among respondents from the UK, Australia and
New Zealand for specific presentations and conditions.
Overall, respondents practising in the UK and New
Zealand indicated they were most likely to prescribe
prefabricated FOs for the majority of presentations and
conditions, whilst respondents in Australia indicated
they were most likely to prescribe customised FOs.
Fig. 5 illustrates the prescription pattern for 1st meta-
tarsophalangeal joint osteoarthritis among respondents
who treat the condition in practice. This pattern
differed for seronegative inflammatory arthritis, con-
nective tissue disease, neurological disorders and
neuromuscular conditions among respondents in the
UK; forefoot pain, Morton’s neuroma, gout, connective
tissue disease and falls prevention among those in
Australia; and tibialis posterior tendon dysfunction
among those in New Zealand (Table 3).
Figures 6 and 7 illustrate FO prescription choices for
diabetes without and with peripheral neuropathy, re-
spectively, among respondents who confirmed that they
treat the condition in practice. When treating diabetes
without peripheral neuropathy, respondents in the UK
were most likely to prescribe prefabricated FOs, whereas
customised FOs were the most frequent prescription
choice for diabetes with peripheral neuropathy. Respon-
dents in Australia reported a range of FO prescription
choices for diabetes without peripheral neuropathy, and
were less likely to prescribe any FO for this condition
compared to prescribing simple, prefabricated or custo-
mised FOs. In contrast, Australian respondents were
most likely to prescribe customised FOs for diabetes
with peripheral neuropathy. Respondents in New Zea-
land were most likely to prescribe prefabricated FOs for
Fig. 2 Most frequently treated patient groups in the UK by working sector
Fig. 3 Most frequently prescribed FO types
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people with diabetes regardless of the presence of per-
ipheral neuropathy, although they were three times more
likely to prescribe customised FOs for diabetes with per-
ipheral neuropathy than without.
Discussion
This study explored and compared the types of FOs cur-
rently prescribed by podiatrists in the UK, Australia and
New Zealand, and reports whether the type of FO pre-
scribed varies between a range of presentations and con-
ditions affecting the back and lower limb. Differences in
the frequency of FO types prescribed per week were
identified between countries. We found that a higher
mean quantity of customised FOs compared to other FO
types were prescribed by Australian respondents, and a
higher mean quantity of prefabricated FOs were pre-
scribed by New Zealand respondents compared to Aus-
tralian respondents. This finding is similar to a previous
study by Landorf et al. [7], in which Australian podia-
trists were found to more frequently prescribe custo-
mised FOs, but podiatrists in New Zealand were three
times more likely than those in Australia to prescribe
prefabricated FOs. In our study, respondents in the UK
demonstrated similar weekly FO prescription habits to
those in New Zealand, as more prefabricated FOs were
prescribed than other FO types, and the mean quantity
of customised FOs prescribed per week was almost
identical. We found that 11% of UK respondents did not
prescribe prefabricated FOs and 20% did not prescribe
customised FOs. These UK findings are similar to work
conducted by Nester et al. [22], where 7% of the UK cli-
nicians (podiatrists, physiotherapists and orthotists) sur-
veyed did not use prefabricated FOs and 25% did not
use customised FOs in practice. Despite these similar-
ities in our UK data, our sample consisted entirely of po-
diatrists, therefore results should not be extrapolated to
other professions.
Differences in FO prescription habits found between
countries may be linked to the sector in which respon-
dents work. The majority (81%) of Australian respon-
dents worked solely in private practice, compared to
35% in the UK and 44% in New Zealand. Findings indi-
cated that although respondents in Australia prescribed
far fewer FOs overall, they prescribed more customised
FOs, which previous studies have shown to be more ex-
pensive to produce than prefabricated and simple FOs
[3, 16]. Differences in the types of FOs prescribed be-
tween UK respondents working in the public sector and
those working in private practice were also identified.
Respondents in the UK public sector prescribed more
simple and prefabricated FOs compared to those work-
ing in private practice, whilst respondents in UK private
practice prescribed more customised FOs. These differ-
ences may reflect NHS cost savings, which present a
Table 2 Prescription habits among UK podiatrists by working sector
Public sector (n = 42) Private sector (n = 44)
Simple FOs PFFOs CFFOs Simple FOs PFFOs CFFOs
Mean (SD)
Range (per week)
2.8 (2.9)
0–10
8.2 (7.8)
0–30
2.2 (6.3)
0–40
1.5 (2.0)
0–10
2.4 (3.2)
0–15
2.6 (4.0)
0–15
No. (%) of respondents not prescribing FO type 7 (16.7%) 2 (4.8%) 14 (33.3%) 4 (9.1%) 6 (13.6%) 5 (11.4%)
No. (%) of respondents who had free choice when prescribing 12 (34%) 9 (25%) 11 (28%) 37 (93%) 34 (89%) 33 (85%)
PFFOs prefabricated functional foot orthoses, CFFOs customised functional foot orthoses
Fig. 4 Percentage of respondents with free choice when prescribing FOs
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fundamental issue within UK public sector healthcare
services [23]. The increased number of customised FOs
prescribed in Australia, compared to the UK and New
Zealand, may also be a result of differences in healthcare
systems and subsequent health insurance schemes that
are in place.
Our study reveals new insights into which FOs podia-
trists prescribe according to the presentation or condition
affecting the lower limb. Differences in FO prescription
habits between countries were evident for specific presen-
tations and conditions. Respondents in the UK and
Australia indicated a preference for customised FOs when
treating diabetes with peripheral neuropathy, despite a
lack of robust evidence supporting these clinical decisions.
For example, in one randomised trial customised FOs
were found to be no better than prefabricated insoles in
reducing the risk of diabetic neuropathic ulceration and
the authors suggested that prefabricated insoles should be
prescribed instead of customised devices where appropri-
ate [9]. However, some international guidelines currently
recommend considering custom-made insoles when a pa-
tient with diabetes has a foot deformity or the skin shows
pre-ulcerative signs [24], which may influence prescription
habits. Respondents in New Zealand were most likely to
prescribe prefabricated FOs for diabetes with and without
peripheral neuropathy compared to other FO types. Al-
though, the higher rate of provision of customised FO for
people with diabetes with peripheral neuropathy, com-
pared to without neuropathy, suggests that the presence
of neuropathy also influenced prescription habits among
New Zealand respondents.
Additionally, the majority of respondents who treated
back pain and hip pain in practice prescribed FOs. Re-
spondents in the UK and New Zealand prescribed more
prefabricated FOs for back pain and hip pain, whilst
those in Australia prescribed more customised FOs. This
Fig. 5 Types of FOs prescribed for 1st metatarsophalangeal joint osteoarthritis
Fig. 6 Types of FOs prescribed for diabetes without peripheral neuropathy
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is despite an absence of evidence for the effectiveness of
any FOs for these presentations [25], and indeed the
NICE guidelines explicitly state that FOs should not be
used in the treatment of lower back pain [26]. However,
as the survey was designed to recruit podiatrists who
prescribed FOs, rather than who treated specific condi-
tions, results may not be representative of the wider
population of podiatrists.
Findings from this study must be considered in the
context of its limitations. Firstly, the open invitation
method of survey distribution did not allow a denom-
inator population of podiatrists to be determined ac-
curately. Although accurate figures are available for
the number of registered podiatrists in each country,
not all of these are members of their professional
body, and professional bodies will not have up to date
email addresses for all members. Therefore formal
calculation of a response rate is not possible. Sec-
ondly, despite efforts to maximise recruitment with
this method, the sample size was lower than hoped
for, which may limit the generalisability of our find-
ings and we note that there are 4800 registered podi-
atrists in Australia, 12,700 in the UK and 450 in New
Zealand. However, the survey did elicit detailed infor-
mation about FO prescription habits for multiple con-
ditions, leading to a compromise between the depth
of information and breadth of population covered.
The survey required participants to select the type of
FO that they would prescribe most frequently for a
range of common presentations and conditions affect-
ing the back and lower limb, and as such, provides a
benchmark of contemporary practice, allowing clini-
cians to reflect on their current FO prescription
habits against national and international patterns.
Some respondents indicated in free text within the
comments section at the end of the survey that they
would not necessarily prescribe FOs based on the
presence of a certain presentation or condition. It was
stated that the decision to prescribe a FO, and the
type of FO prescribed, would depend on the individ-
ual and whether they were symptomatic or not, fac-
toring in pain levels, foot shape, deformity, and joint
range of motion. Several participants also identified
that the type of FO prescribed for a certain condition
would depend on the patient’s financial situation or
their footwear. Gaining deeper insight into the clinical
decision-making processes that underpin FO prescrip-
tion was beyond the scope of this survey, but clini-
cians’ choices in relation to prescribing FOs for
specific lower limb pathologies across different coun-
tries and healthcare sectors is certainly an area for fu-
ture research.
Conclusions
This study has identified that FO prescription habits
vary depending on the country of practice, the
healthcare sector in which practitioners work, and
the condition targeted. Australian respondents, the
majority of whom worked in private practice, pre-
scribed far fewer devices overall, but when they did
prescribe, they were more likely to prescribe custo-
mised FOs. In contrast, prefabricated FOs were more
frequently prescribed in the UK and New Zealand,
where there was more variation in working sector.
FO prescription habits for diabetes differed accord-
ing to whether or not peripheral neuropathy was
present. An increased percentage of respondents pre-
scribed customised FOs for diabetes with peripheral
neuropathy compared to diabetes without peripheral
neuropathy, independent of country of practice.
These findings provide insights into contemporary
clinical practice.
Fig. 7 Types of FOs prescribed for diabetes with peripheral neuropathy
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